|

Anti-CD19-CAR CMV-specific T-lymphocytes Clinical Trials

3 actively recruiting trials across 1 location

Also known as: Anti-CD19-CAR CMV-specific T-cells, CMV-specific CD19 CAR-T Cells, CMV-specific CD19-CAR T Cells, CMV-specific CD19-CAR T Cells (SY); CMV-specific CD19 CAR-T Cells (SY); Anti-CD19-CAR CMV-specific T-cells (SY)

Pipeline

Early 1: 1Phase 1: 2

Top Sponsors

  • City of Hope Medical Center3

Indications

  • Cancer3
  • Recurrent B-Cell Non-Hodgkin Lymphoma2
  • Intermediate Grade B-Cell Non-Hodgkin's Lymphoma1
  • High Grade B-Cell Non-Hodgkin's Lymphoma1
  • Refractory B-Cell Non-Hodgkin Lymphoma1

Duarte, California3 trials

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

City of Hope Medical Center

Early 1
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

City of Hope Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.